Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

Forbes: Faster FDA Approvals Have Not Caused More Drug Safety Problems

FDA115x76

In 1992, Congress, industry, and the FDA worked together to create the Prescription Drug User Fee Act (PDUFA). This program ensures that FDA has the ability to hire additional reviewers to expedite the drug review process by having industry pay “user fees.” Recently, attention has been given to a flawed study in the August 2014 issue of Health Affairs, which has some critics claiming that PDUFA fees are biasing FDA review decisions. The study looked at Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Jim Greenwood in WSJ: Curing Hepatitis C Is Cheaper Than Open-Ended Care

Jim Greenwood

On Friday, a letter from BIO President and CEO Jim Greenwood was published in the Wall Street Journal, arguing that curing hepatitis C is cheaper than the alternative of open ended care. The full text of the letter is below: President and CEO of America’s Health Insurance Plans (HIP) Karen Ignagni’s “Paying for the Thousand-Dollar Pill” (op-ed, Aug. 4) plays down the fact that Sovaldi has been shown to achieve a high cure rate for Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

Delivering on Biotech’s Promise to Treat Anthrax, Smallpox, Ebola

Jim Greenwood

Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, each year America is better equipped to respond to potential biological, chemical, nuclear and radiological threats, BIO president and CEO Jim Greenwood says in a Roll Call op-ed published today. With recent anthrax and smallpox incidents at CDC and NIH labs,  which fortunately did not lead to any human exposure,  it’s worth taking a look at how we might respond Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech CEOs Speak Out on JOBS Act Success

Biotech IPOs Infographic

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. The JOBS Act reached a major milestone last week, with the 100th company going public under its provisions. On October 7th at the 13th Annual BIO Investor Forum, we Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

New Report: Innovation in Hepatitis C Treatment

CHI

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis C and the potential of groundbreaking new treatments to save tens of thousands of lives over the coming decades. Innovation in Hepatitis C Treatment: New Opportunities for Action explores the incredible progress that has been made in Hepatitis C treatment in the decades since the Hepatitis C virus was identified as the cause of the disease in 1989. Early treatments Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,